Evidence map›Paper›PMID 36598130›Full record

ArticleHistology and histopathology2024

Catalpol protects mouse ATDC5 chondrocytes against interleukin-1β-induced catabolism.

Chengkui Cai, Pengcheng Sun, Zhihui Chen, Chao Sun, Liying Tian

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Chengkui CaiDepartment of Orthopedics, The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, PR China.
Pengcheng SunDepartment of Orthopedics, The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, PR China.
Zhihui ChenDepartment of Orthopedics, The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, PR China.
Chao SunDepartment of Orthopedics, The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, PR China.
Liying TianDepartment of Anesthesiology, The Second Affiliated Hospital of Air Force Medical University, Xi' an, Shaanxi, PR China. tianly0323@yeah.net.
Affiliated Hospital of Shaanxi University of Chinese Medicine · CNXi'an Medical University · CN

Funding

Second Affiliated Hospital of Air Force Medical University SAHSGMU-2018U03
6 · The paper itself

Abstract

Catalpol is a natural product with promising anti-inflammatory effects, however, its effects on chondrocytes and osteoarthritis (OA) have not been well investigated. OA is a painful and debilitating joint disease that affects people worldwide. Traditional Chinese Medicine has been sought to treat OA, including the Rehmannia extract, Catalpol. Here, we examined the effects of Catalpol, a plant derivative used in traditional Chinese medicine, on ATDC5 chondrocytes originating from mouse teratocarcinoma cells stimulated with interleukin-1β (IL-1β) to mimic the OA cellular environment. Catalpol significantly reduced matrix metalloproteinase-1, -3, -13 (MMP-1, -3, -13), a disintegrin and metalloproteinase with thrombospondin motifs -4, -5 (ADAMTS-4, -5) against IL-1β, demonstrating a likely anti-cartilage degradation activity. We also found that Catalpol exerted a significant anti-oxidative stress effect by downregulating the production of inducible nitric oxide synthase (iNOS), nitric oxide (NO), reactive oxygen species (ROS), and malondialdehyde (MDA). Catalpol treatment significantly reduced the levels of several key inflammatory factors, including Prostaglandin E₂ (PGE₂), cyclooxygenase-2 (COX-2), interleukin-8 (IL-8), and monocyte chemoattractant protein-1 (MCP-1). We further demonstrate that the effects of Catalpol were mediated by the nuclear factor -κB (NF-κB) pathway via downregulation of the phosphorylation of inhibitor of nuclear factor κB-α (IκBα). This was confirmed by measuring p38 and p65 protein levels as well as the luciferase activity of NF-κB. Altogether, we demonstrate the potential of Catalpol as a novel treatment agent against cartilage matrix degradation, oxidative stress, and inflammation in OA.

Indexed as

ChondrocytesIridoid GlucosidesOsteoarthritisAnimalsAnti-Inflammatory AgentsHumansInflammationInterleukin-1betaMiceNF-kappa BAnti-Inflammatory AgentscatalpolInterleukin-1betaIridoid GlucosidesNF-kappa B

Identifiers

PMID36598130
OpenAlexW4313487885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.